Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD74 antigen, also known as the invariant chain, is a type II transmembrane glycoprotein that associates with MHC class II molecules and directs their intracellular transport, folding, and assembly, ensuring correct antigen presentation to CD4+ T cells. CD74 blocks premature peptide loading by occupying the binding cleft, and its regulated digestion results in a controlled exchange of peptides in endosomes. CD74 also acts as a receptor for the cytokine macrophage migration inhibitory factor (MIF), mediating signal transduction pathways important for cell survival, inflammation, and carcinogenesis. Its expression on cell surfaces is associated with chronic inflammatory conditions and cancers, making it a therapeutic target in inflammatory diseases and certain lymphomas.
Blockade of CD74 inhibits MIF signaling, reduces chronic inflammation, and impairs malignant cell survival/proliferation Targeting CD74 disrupts antigen presentation pathways critical for immune activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD74 antigen (invariant chain of major histocompatibility complex, class II antigen-associated) (CD74).